BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

637 related articles for article (PubMed ID: 27110099)

  • 1. Xyloketal-derived small molecules show protective effect by decreasing mutant Huntingtin protein aggregates in Caenorhabditis elegans model of Huntington's disease.
    Zeng Y; Guo W; Xu G; Wang Q; Feng L; Long S; Liang F; Huang Y; Lu X; Li S; Zhou J; Burgunder JM; Pang J; Pei Z
    Drug Des Devel Ther; 2016; 10():1443-51. PubMed ID: 27110099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TBK1 phosphorylates mutant Huntingtin and suppresses its aggregation and toxicity in Huntington's disease models.
    Hegde RN; Chiki A; Petricca L; Martufi P; Arbez N; Mouchiroud L; Auwerx J; Landles C; Bates GP; Singh-Bains MK; Dragunow M; Curtis MA; Faull RL; Ross CA; Caricasole A; Lashuel HA
    EMBO J; 2020 Sep; 39(17):e104671. PubMed ID: 32757223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Small Molecules that Induce the Degradation of Huntingtin.
    Tomoshige S; Nomura S; Ohgane K; Hashimoto Y; Ishikawa M
    Angew Chem Int Ed Engl; 2017 Sep; 56(38):11530-11533. PubMed ID: 28703441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat.
    Clemens LE; Weber JJ; Wlodkowski TT; Yu-Taeger L; Michaud M; Calaminus C; Eckert SH; Gaca J; Weiss A; Magg JC; Jansson EK; Eckert GP; Pichler BJ; Bordet T; Pruss RM; Riess O; Nguyen HP
    Brain; 2015 Dec; 138(Pt 12):3632-53. PubMed ID: 26490331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a potent small molecule inhibiting Huntington's disease (HD) pathogenesis via targeting CAG repeats RNA and Poly Q protein.
    Khan E; Mishra SK; Mishra R; Mishra A; Kumar A
    Sci Rep; 2019 Nov; 9(1):16872. PubMed ID: 31728006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Marine derived xyloketal derivatives exhibit anti-stress and anti-ageing effects through HSF pathway in Caenorhabditis elegans.
    Zhou JB; Zheng YL; Zeng YX; Wang JW; Pei Z; Pang JY
    Eur J Med Chem; 2018 Mar; 148():63-72. PubMed ID: 29454917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. G3BP1-dependent mechanism suppressing protein aggregation in Huntington's models and its demise upon stress granule assembly.
    Gutiérrez-Garcia R; Koyuncu S; Hommen F; Bilican S; Lee HJ; Fatima A; Vilchez D
    Hum Mol Genet; 2023 May; 32(10):1607-1621. PubMed ID: 36611004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological characterization of mutant huntingtin aggregate-directed PET imaging tracer candidates.
    Herrmann F; Hessmann M; Schaertl S; Berg-Rosseburg K; Brown CJ; Bursow G; Chiki A; Ebneth A; Gehrmann M; Hoeschen N; Hotze M; Jahn S; Johnson PD; Khetarpal V; Kiselyov A; Kottig K; Ladewig S; Lashuel H; Letschert S; Mills MR; Petersen K; Prime ME; Scheich C; Schmiedel G; Wityak J; Liu L; Dominguez C; Muñoz-Sanjuán I; Bard JA
    Sci Rep; 2021 Sep; 11(1):17977. PubMed ID: 34504195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aggregation landscapes of Huntingtin exon 1 protein fragments and the critical repeat length for the onset of Huntington's disease.
    Chen M; Wolynes PG
    Proc Natl Acad Sci U S A; 2017 Apr; 114(17):4406-4411. PubMed ID: 28400517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective effects of xyloketal B against MPP+-induced neurotoxicity in Caenorhabditis elegans and PC12 cells.
    Lu XL; Yao XL; Liu Z; Zhang H; Li W; Li Z; Wang GL; Pang J; Lin Y; Xu Z; Chen L; Pei Z; Zeng J
    Brain Res; 2010 May; 1332():110-9. PubMed ID: 20347725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The dynamics of early-state transcriptional changes and aggregate formation in a Huntington's disease cell model.
    van Hagen M; Piebes DGE; de Leeuw WC; Vuist IM; van Roon-Mom WMC; Moerland PD; Verschure PJ
    BMC Genomics; 2017 May; 18(1):373. PubMed ID: 28499347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Huntingtin protein: A new option for fixing the Huntington's disease countdown clock.
    Caterino M; Squillaro T; Montesarchio D; Giordano A; Giancola C; Melone MAB
    Neuropharmacology; 2018 Jun; 135():126-138. PubMed ID: 29526547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new Caenorhabditis elegans model of human huntingtin 513 aggregation and toxicity in body wall muscles.
    Lee AL; Ung HM; Sands LP; Kikis EA
    PLoS One; 2017; 12(3):e0173644. PubMed ID: 28282438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short G-rich oligonucleotides as a potential therapeutic for Huntington's Disease.
    Skogen M; Roth J; Yerkes S; Parekh-Olmedo H; Kmiec E
    BMC Neurosci; 2006 Oct; 7():65. PubMed ID: 17014717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Herp Promotes Degradation of Mutant Huntingtin: Involvement of the Proteasome and Molecular Chaperones.
    Luo H; Cao L; Liang X; Du A; Peng T; Li H
    Mol Neurobiol; 2018 Oct; 55(10):7652-7668. PubMed ID: 29430620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Gpr52 lowers mutant HTT levels and rescues Huntington's disease-associated phenotypes.
    Song H; Li H; Guo S; Pan Y; Fu Y; Zhou Z; Li Z; Wen X; Sun X; He B; Gu H; Zhao Q; Wang C; An P; Luo S; Hu Y; Xie X; Lu B
    Brain; 2018 Jun; 141(6):1782-1798. PubMed ID: 29608652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small-Molecule Disruptors of Mutant Huntingtin-Calmodulin Protein-Protein Interaction Attenuate Deleterious Effects of Mutant Huntingtin.
    Kapadia K; Trojniak AE; Guzmán Rodríguez KB; Klus NJ; Huntley C; McDonald P; Roy A; Frankowski KJ; Aubé J; Muma NA
    ACS Chem Neurosci; 2022 Aug; 13(15):2315-2337. PubMed ID: 35833925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computational insights into missense mutations in HTT gene causing Huntington's disease and its interactome networks.
    Khan MQ; Mubeen H; Khan ZQ; Masood A; Zafar A; Wattoo JI; Nisa AU
    Ir J Med Sci; 2023 Jun; 192(3):1435-1445. PubMed ID: 35829908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pathobiology of perturbed mutant huntingtin protein-protein interactions in Huntington's disease.
    Wanker EE; Ast A; Schindler F; Trepte P; Schnoegl S
    J Neurochem; 2019 Nov; 151(4):507-519. PubMed ID: 31418858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and neuroprotective action of xyloketal derivatives in Parkinson's disease models.
    Li S; Shen C; Guo W; Zhang X; Liu S; Liang F; Xu Z; Pei Z; Song H; Qiu L; Lin Y; Pang J
    Mar Drugs; 2013 Dec; 11(12):5159-89. PubMed ID: 24351912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.